Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

NECT (HAT)

 
 

NECT = Nifurtimox-Eflornithine Combination Therapy

NECT is the first new, improved treatment option in 25 years for stage 2 (advanced stage) human African trypanosomiasis (HAT) also known as sleeping sickness. It consists of a simplified coadministration of nifurtimox, which is given orally, and eflornithine, which is given intravenously.

  • Launched in 2009
  • Included  in the Essential Medicines List (EML) of the WHO since 2009
  • Much safer than Melarsoprol, a highly toxic, arsenic-based drug that kills 5% of treated patients, still used in 50% of patients.
  • Compared to eflornithine monotherapy, the best previously available treatment for stage 2 HAT, NECT is:
    • As effective
    • Safer
    • Easier to administer
    • More cost-effective
    • Requests shorter hospitalisation
  • The result of a six-year partnership between NGOs, governments, pharmaceutical companies, and the WHO.
  • Donated by Sanofi and Bayer Schering Pharma AG
  • Available in 12 African countries that account for 99% of reported HAT cases
  • Represents 93% of HAT treatments distributed  in DRC in 2011

Download NECT dossier in English [PDF 350KB]
Téléchargez le dossier NECT en français [PDF 317KB]
Read more about NECT project

  NECT News
Watch NECT video

On youtube!
- in English
- en français
Implementation progress
Available in 12 African countries

Request supply signed by Congo and Guinea
Recent Scientific Publications
PLos one, October 2012
Nifurtimox-Eflornithine
Combination Therapy (NECT) for second stage gambiense
human African trypanosomiasis: MSF experience in the Democratic Republic of
the Congo

PLos NTDs, May 2010
NECT is Next: Implementing the new drug combination therapy for trypanosoma brucei gambiense Sleeping sickness
 


Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License